FDA Reverses Course on Huntington's Disease Drug Application, Renewing Debate Over Rare Disease Approval Process

The Food and Drug Administration's handling of uniQure's experimental Huntington's disease therapy drew attention after the agency reportedly agreed to allow the company to seek approval, then withdrew that agreement, then reversed course again following pressure from patient advocates who escalated their concerns to the White House. Huntington's disease is a rare, inherited disorder that progressively destroys nerve cells in the brain.

The Washington Examiner, which published the account as an opinion piece by healthcare consultant Matt Cover, framed the episode not primarily as a story about the specific uniQure drug, but as evidence of a broader pattern: an agency it characterized as "notoriously bureaucratic" applying its protocols inconsistently and without regard to patients facing terminal illness. Cover wrote that for families without treatment options, "the risk is 100% early death," and questioned whether anyone could credibly argue the current approval process is as efficient as it could be.

Cover drew on several examples to argue that approvals of experimental treatments for rare diseases generate long-term medical value. He cited ibuprofen, originally a prescription drug for rheumatoid arthritis; gabapentin, first approved for epilepsy and now widely prescribed for nerve pain and other conditions; and GLP-1 drugs like Ozempic, originally a diabetes treatment. He described these as evidence of an "upstream-to-downstream" innovation model that depends on initial rare-disease approvals.